In a report released today, Charles Duncan from Cantor Fitzgerald maintained a Buy rating on Halozyme (NASDAQ: HALO), with a price target of $27. The company’s shares opened today at $14.53, close to its 52-week low of $14.33.
Duncan noted:
“We are OW with a $27 PT. The ENHANZE partnerships have recently expanded & include multiple shots on goal, with the reformulation of JNJ’s DARZALEX in P3 studies being most advanced. We believe these partnerships represent multiple value inflection points and, almost irrespective of the outcome of PC, drive our favorable perspective.”
According to TipRanks.com, Duncan is a 2-star analyst with an average return of 0.6% and a 43.5% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, KalVista Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.
Halozyme has an analyst consensus of Moderate Buy, with a price target consensus of $21.67.
See today’s analyst top recommended stocks >>
The company has a one-year high of $21.48 and a one-year low of $14.33. Currently, Halozyme has an average volume of 866.7K.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Halozyme Therapeutics, Inc. is a biopharmaceutical company specializes in research, development, and commercialization of human enzymes and other drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant.
